Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Chanez (Marseille, France). Recommendations of new therapies for severe asthma and the future. Annual Congress 2013 –ERS/ATS Task Force report on severe asthma

Member's Comments

No comment yet.

Related content which might interest you: Recommended new therapies for severe asthma and the future Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop Year: 2014 A pragmatic guide to choosing biologic therapies in severe asthma Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021 Year: 2021 Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 Do we need new therapies for noneosinophilic asthma? Source: Annual Congress 2004 - Noneosinophilic asthma Year: 2004 New and future developments of therapy for asthma in children Source: Eur Respir Mon 2012; 56: 224-234 Year: 2012 From guidelines to personalized treatment of children with asthma Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 Current and future preventive and treatment strategies in CLAD Source: International Congress 2015 – When chronic inflammation drives fibrosis: a lesson from lung transplantation Year: 2015 Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement Source: Eur Respir J, 52 (5) 1801261; 10.1183/13993003.01261-2018 Year: 2018 A new GINA resource in 2018: a practical guide for assessing and managing difficult-to-treat and severe asthma Source: International Congress 2018 – GINA 2018 and beyond: shaping the future of asthma management Year: 2018 Recommendations for pharmacological treatment of exacerbations of COPD Source: International Congress 2017 – Treatment and prevention of COPD exacerbation Year: 2017 A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 The new guidelines for management of work-related asthma Source: Eur Respir J 2012; 39: 518-519 Year: 2012 Challenges in COPD exacerbations and future research and unknowns Source: Annual Congress 2013 –Recommendations from the ERS/ATS Guideline on COPD Exacerbation Prevention Year: 2013 Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children Source: Eur Respir J 2006; 28: Suppl. 50, 481s Year: 2006 How do the new guidelines work? Practical approach to the new guidelines for asthma diagnosis in children, discussion and Q&A Source: Virtual Congress 2021 – The ERS guidelines for the diagnosis of asthma in children aged 5-16 years Year: 2021 Future directions: preventing and treating asthma Source: International Congress 2016 – Childhood wheeze: are we making any progress? Year: 2016 Filling the gaps: future treatment options for mild asthma Source: International Congress 2018 – The complexities of managing mild asthma Year: 2018